4//SEC Filing
Williams Michelle LeRoux 4
Accession 0001415889-24-021196
CIK 0001708527other
Filed
Aug 12, 8:00 PM ET
Accepted
Aug 13, 5:00 PM ET
Size
9.6 KB
Accession
0001415889-24-021196
Insider Transaction Report
Form 4
ELUTIA INC.ELUT
Williams Michelle LeRoux
CHIEF SCIENTIFIC OFFICER
Transactions
- Exercise/Conversion
Class A Common Stock
2024-08-12+50,000→ 67,100 total - Tax Payment
Class A Common Stock
2024-08-12$2.84/sh−15,800$44,872→ 51,300 total - Exercise/Conversion
Restricted Stock Units
2024-08-12−50,000→ 0 total→ Class A Common Stock (50,000 underlying)
Footnotes (4)
- [F1]Transaction represents shares of the Issuer's Class A Common Stock received from the vesting of restricted stock units.
- [F2]Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
- [F3]Shares withheld by the Issuer to satisfy tax withholding requirements on vesting of restricted stock units.
- [F4]On January 31, 2024, the Reporting Person was granted 50,000 restricted stock units. The restricted stock units vested on the 10th business day following the clearance by the U.S. Food & Drug Administration ("FDA") of the Company's CanGarooRM antibiotic-eluting biologic envelope, unless such date is not during one of the Company's open trading windows, in which case such RSUs vested as of the first business day of the next open trading window. The CanGarooRM antibiotic-eluting biologic envelope, now known as EluPro, was cleared by the FDA on June 14, 2024 and the first business day of the next open trading window was August 12, 2024.
Documents
Issuer
ELUTIA INC.
CIK 0001708527
Entity typeother
Related Parties
1- filerCIK 0001398249
Filing Metadata
- Form type
- 4
- Filed
- Aug 12, 8:00 PM ET
- Accepted
- Aug 13, 5:00 PM ET
- Size
- 9.6 KB